Country¹

Perceived patient eligibility for BsAbs appeared to be consistent among HCPs, while that for CAR T-cell therapy was varied across countries

Reference

1. Zamagni E, Kevin B, Cormier N, et al. Differences across countries in healthcare provider confidence with CAR-T and bispecific antibody therapies for relapsed/refractory multiple myeloma. Presented at: EHA 2025 Congress; June 12-15, 2025; Milan, Italy. Poster PS1751.